Shay Capital LLC Invests $91,000 in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Shay Capital LLC purchased a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,862 shares of the company’s stock, valued at approximately $91,000.

Several other hedge funds have also recently modified their holdings of CRDF. Orbimed Advisors LLC purchased a new position in shares of Cardiff Oncology in the fourth quarter worth $6,677,000. Acorn Capital Advisors LLC purchased a new position in shares of Cardiff Oncology in the fourth quarter worth $6,260,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Cardiff Oncology in the fourth quarter worth $5,609,000. Laurion Capital Management LP purchased a new position in shares of Cardiff Oncology in the fourth quarter worth $2,504,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Cardiff Oncology in the fourth quarter worth $2,207,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price target on Cardiff Oncology from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, May 9th.

Cardiff Oncology Stock Performance

Cardiff Oncology stock opened at $2.81 on Friday. The stock has a market cap of $186.94 million, a PE ratio of -2.99 and a beta of 1.81. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $5.64. The stock has a fifty day moving average of $3.03 and a 200 day moving average of $3.46.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. As a group, sell-side analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.